Stock Quote

The shares of Vanguard Pharmaceutical Corp are quoted on the OTC under the symbol VGPH.

---

San Antonio, Texas - December 1, 2008 - Vanguard Pharmaceutical Corp., (OTC:VGPH)-a company who has joined the fight against cancer by selling affordable generic oncology drugs and researching noninvasive cures for cancer is now in negotiations with a biotechnology company who has an effective delivery method for telomerase therapies. Vanguard is negotiating to either acquire or gain a significant stake in the company.

Telomerase therapy is a revolutionary technology that can kill cancer by stopping the production of cancer cells without harming other cells and it can become our fountain of youth by regenerating cells to treat aging and age related diseases. When a cell contains telomerase it re-lengthens telomeres which are a repeating DNA structure at the ends of each chromosome that shorten with each cell division and eventually kills the cell.
Cancer cells are immortal because they contain telomerase which allows the cancerous cells to continually divide and replicate without limit. Telomerase inhibitors will rapidly kill cancer cells by shortening its telomeres.

Normal body cells are mortal and slow down when their telomeres shorten. They do not contain telomerase to keep them youthful. Telomerase activators have shown to increase telomere length which can restore skins youthful appearance and can heal arthritic joints or cardiovascular tissue.

Telomerase therapy can kill cancer and rejuvenate cells however the barrier to the technology has been an effective method to deliver telomerase therapy in living organisms. The company Vanguard is in negotiations with has a delivery technology that for the firsttime makes practical the delivery of telomerase therapies to cells and tissues in a living organism.

---

---

"The position of President of Vanguard Pharmaceutical is an outstanding opportunity to lead a company with a promising future," said Mr. Fernandez. "I look forward to advancing our development in South America and believe my network and connections in Peru and Brazil will be an invaluable asset."

The Board of Directors at Vanguard is thrilled with Raul's experience and leadership. They would like to wish Francine Peres all the best as she relinquished her duties to allow for more personal family time.

---

SAN ANTONIO, TX, Jul 31 (MARKET WIRE) --
Vanguard Pharmaceutical Corp., (PINKSHEETS: VGPH) -- a company providing the market with affordable and safe generic medicines has been granted a 10 year exclusive sales contract from Arbro Pharmaceutical Limited for the sale of its pharmaceutical products in Latin America and the Caribbean.

Arbro has over 150 generic drugs that are regularly exported, is internationally accredited for Good Manufacturing Practices (GMP), follows the WHO guidelines, and is ISO 9001-2000 certified. Further, its internal testing labs provide a high standard of quality control and bioequivalence accreditation.

Vanguard's strategic alliance with Arbro will ensure delivery of high quality products at affordable prices. Vanguard has performed a market price analysis of Arbro's drugs in Brazil, Peru, and Paraguay and has found their prices to be significantly lower than recent tenders granting them a huge opportunity in these countries.

---

In an era of aging populations, rising health care costs, and increasing cancer cases Vanguard's mission is to decrease health care expenditures by selling affordable oncology and generic drugs and by investing in research to find a noninvasive cure for cancer.

Generic medicines allow patients to access safe, effective, high-quality medicines at 10%-80% of the price of branded originator medicines. In this way, generic medicines support the sustainability of health care provision and contribute to controlling pharmaceutical expenditure.  Vanguard is currently targeting Latin America for its oncology and generic pharmaceutical sales as it is believed to have a substantially unmet demand for advanced generics and entry into the market can be done with relative ease. Latin America is set to emerge as a globally significant market and its generics market is conservatively expected to reach US$6.4 billion by the year-end of 2009.

A noninvasive cure for cancer will revolutionize our health care system by highly reducing hospital stays as patients will not have to go through life threatening chemotherapy and radiation which could save health care systems billions of dollars. Vanguard's team is researching several new technologies such as telomerase inhibitor therapy and low power radio frequency radiation.  Vanguard plans to partner with established clinical centers and universities to further develop these technologies then license them out.  It has also discussed performing trials in Latin American oncology centers.  

---